Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease

Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such therapy. Previous studies have demonstrated a pro-in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomolecules (Basel, Switzerland) Jg. 13; H. 6; S. 954
Hauptverfasser: Hanić, Maja, Vučković, Frano, Deriš, Helena, Bewshea, Claire, Lin, Simeng, Goodhand, James R., Ahmad, Tariq, Trbojević-Akmačić, Irena, Kennedy, Nicholas A., Lauc, Gordan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 01.06.2023
MDPI
Schlagworte:
adalimumab
Anti-inflammatory agents
Anti-Inflammatory Agents - pharmacology
Anti-Inflammatory Agents - therapeutic use
Biological Factors - therapeutic use
Biological Products - therapeutic use
Biomarkers
Chromatography
Crohn Disease - drug therapy
Crohn's disease
Cytotoxicity
Dosage and administration
Gastrointestinal tract
Glycoproteins
Health aspects
Humans
IgG glycosylation
Immunoglobulin G
Immunoglobulin G - therapeutic use
Inflammation
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory diseases
Infliximab
Labeling
Medical research
Medicine, Experimental
Monoclonal antibodies
N-glycans
PANTS study
Physiological aspects
Polysaccharides
Proteins
Quality of Life
Research ethics
Tumor necrosis factor inhibitors
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor Necrosis Factor-alpha
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Well being
Croatia
United States > US
PANTS study
IgG glycosylation
infliximab
adalimumab
Crohn’s disease
ISSN:2218-273X, 2218-273X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such therapy. Previous studies have demonstrated a pro-inflammatory pattern in the composition of CD patients’ immunoglobulin G (IgG) N-glycome compared to healthy individuals. Here, we utilised the high-throughput UHPLC method for N-glycan analysis to explore the longitudinal effect of the anti-TNF drugs infliximab and adalimumab on N-glycome composition of total serum IgG in 198 patients, as well as the predictive potential of IgG N-glycans at baseline to detect primary non-responders to anti-TNF therapy in 1315 patients. We discovered a significant decrease in IgG agalactosylation and an increase in monogalactosylation, digalactosylation and sialylation during the 14 weeks of anti-TNF treatment, regardless of therapy response, all of which suggested a diminished inflammatory environment in CD patients treated with anti-TNF therapy. Furthermore, we observed that IgG N-glycome might contain certain information regarding the anti-TNF therapy outcome before initiating the treatment. However, it is impossible to predict future primary non-responders to anti-TNF therapy based solely on IgG N-glycome composition at baseline.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Membership of the PANTS Consortium is provided in Supplementary Table S2.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom13060954